TRexBio Secures $50M to Advance Precision Treg Therapies
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
GEORGE TOWN, CAYMAN ISLANDS | January 26, 2026 — Moolec Science S.A. announced that Nasdaq Staff has issued a...
KING OF PRUSSIA, PENNSYLVANIA | January 26, 2026 — Phio Pharmaceuticals has announced its participation in the Third Annual...
Boulder, Colorado, January 20, 2026 — Think Bioscience, a privately held biotechnology company focused on unlocking historically “undruggable” drug...
MENLO PARK, Calif., January 12, 2026 — Inquis Medical, a commercial-stage medical technology company focused on venous thromboembolic disease...
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
CORAL GABLES, Fla., November 4, 2025 — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biopharmaceutical company focused on developing...
LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by...
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2025 — Star Therapeutics announced it has closed an oversubscribed $125 million Series...
PARIS, Sept. 24, 2025 — Sanofi announced a $625 million capital expansion for its corporate venture fund, Sanofi Ventures,...
